CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: phototherapy</title> <meta name="description" content="Search results for: phototherapy"> <meta name="keywords" content="phototherapy"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="phototherapy" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="phototherapy"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 13</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: phototherapy</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">13</span> The Use of Phototherapy with Unusual Case Studies in Counselling</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Briar%20Schulz">Briar Schulz</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The use of phototherapy within the counselling room offers significant advantages in extending far beyond typical "talk therapy" avenues. The benefits of using this approach are numerous and include: efficiency in recalling pertinent information in addition to utilizing a visual lens that often captures opulent detail that can be eluded in traditional dialogue. The goal of this presentation is to provide conference attendees with an opportunity to understand the therapeutic benefits and creative possibilities of incorporating photography into the clinical counselling process. This includes practical strategies for using in specific case studies, where studies of phototherapy have previously been limited. Ethical considerations and limitations to the process will also be addressed. Attendees will observe the benefits of using phototherapy with six longitudinal case studies including: a 30 year old female, with anorexia nervosa; a 22 year old self-harming individual with obsessive compulsive disorder; a 24 year old client with developmental delays, and bipolar disorder; a 14 year old client with Autism; and two clients with rare medical conditions struggling with depression and anxiety, one 21 years old and the other 16 years old. Aspects of each case will be linked to various theoretical modalities to highlight the efficiency and benefits of phototherapy in drawing important clinical conclusions. Furthermore, the use of phototherapy within these clinical areas remains a relatively unexplored area of the literature, and possibilities for future research will be highlighted. Finally, conference attendees will have the opportunity to try various phototherapy strategies within the interactive portion of this presentation. . <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Atypical" title="Atypical">Atypical</a>, <a href="https://publications.waset.org/abstracts/search?q=Case%20studies" title=" Case studies"> Case studies</a>, <a href="https://publications.waset.org/abstracts/search?q=Phototherapy" title=" Phototherapy"> Phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=Photovoice" title=" Photovoice"> Photovoice</a> </p> <a href="https://publications.waset.org/abstracts/124002/the-use-of-phototherapy-with-unusual-case-studies-in-counselling" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/124002.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">149</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">12</span> Nanoceutical Intervention (Nanodrug) of Neonatal Hyperbilirubinemias Compared to Conventional Phototherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Samir%20Kumar%20Pal">Samir Kumar Pal</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Targeted rapid degradation of bilirubin has the potential to thwart incipient bilirubin encephalopathy. Uncontrolled hyperbilirubinemia is a potential problem in developing countries, including India, because of the lack of reliable healthcare institutes for conventional phototherapy. In India, most of the rural subjects duel in the exchange limit during transport, leading to a risk of kernicterus when they arrive at the treatment centre. Thus, an alternative pharmaceutical agent is needed for the hours. Objective: Exploration of a distinct therapeutic strategy for the control of neonatal hyperbilirubinemia compared to conventional phototherapy in a clinical setting. Method: We synthesized, characterized and investigated a spinel-structured Manganese citrate nanocomplex (C-Mn₃O₄ NC, the nanodrug) along with conventional phototherapy in neonatal subjects. We have also observed BIND scores in order to assess neurological dysfunctions. Results: Our observational study clearly reveals that the rate of declination of bilirubin in neonatal subjects with nanodrug oral administration and phototherapy is faster compared to that in the case of phototherapy only. The associated neural dysfunctions were also found to be significantly lower in the case of combined therapy. Conclusion: This study demonstrates that combined therapy works better than conventional phototherapy only for the control of hyperbilirubinemia. We have observed that a significant portion of neonatal subjects requiring blood exchange has been prevented with the combined therapeutic strategy. Further compilation of a drug-safety-dossier is warranted to translate this novel therapeutic chemo preventive approach to clinical settings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nanodrug" title="nanodrug">nanodrug</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticle" title=" nanoparticle"> nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=Neonatal%20hyperbilirubinemia" title=" Neonatal hyperbilirubinemia"> Neonatal hyperbilirubinemia</a>, <a href="https://publications.waset.org/abstracts/search?q=alternative%20to%20phototherapy" title=" alternative to phototherapy"> alternative to phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=redox%20modulation" title=" redox modulation"> redox modulation</a>, <a href="https://publications.waset.org/abstracts/search?q=redox%20medicine" title=" redox medicine"> redox medicine</a> </p> <a href="https://publications.waset.org/abstracts/184402/nanoceutical-intervention-nanodrug-of-neonatal-hyperbilirubinemias-compared-to-conventional-phototherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/184402.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">59</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">11</span> Cutaneous Sarcoidosis Treated with Narrow Band Ultraviolet B (NBUVB) Phototherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hannah%20Riva">Hannah Riva</a>, <a href="https://publications.waset.org/abstracts/search?q=Sarah%20Mazal"> Sarah Mazal</a>, <a href="https://publications.waset.org/abstracts/search?q=Jessica%20L.%20Marquez"> Jessica L. Marquez</a>, <a href="https://publications.waset.org/abstracts/search?q=Michael%20Rains"> Michael Rains</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A 70-year-old female with a Fitzpatrick skin phenotype II presented with a 13-year history of a scaly rash located on the left breast and bilateral pretibial regions. The patient’s past medical history was otherwise unremarkable, with the exception of surgery involving the left breast. Physical examination revealed infiltrative hyperpigmented scaly plaques and nodules located on the left breast and pretibial regions bilaterally. A negative systemic workup excluded organ involvement. A clinical diagnosis of cutaneous sarcoidosis was made. Prior treatments included triamcinolone 0.1% topical cream and clobetasol 0.05% ointment, which failed to show improvement. Full-body narrow-band UVB (NBUVB) treatment was performed on a tri-weekly basis for eight months. NBUVB dosage was slowly titrated from 300 mJ/cm2 to a final dose of 1800 mJ/cm2 to prevent discomfort and burning sensations. Throughout the duration of her treatment, the patient adhered to a regimen of clobetasol 0.05% topical ointment applied twice daily in two-week intervals. Improvement was noticed after two months, with continued improvement up to eight months. The patient is continuing NBUVB phototherapy treatments for maintenance. In our case, NBUVB phototherapy treatment demonstrated promising results with improvement after two months of treatment. Physicians should consider NBUVB phototherapy as an effective option for patients presenting with cutaneous sarcoidosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=dermatology" title="dermatology">dermatology</a>, <a href="https://publications.waset.org/abstracts/search?q=sarcoidosis" title=" sarcoidosis"> sarcoidosis</a>, <a href="https://publications.waset.org/abstracts/search?q=phototherapy" title=" phototherapy"> phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=ultraviolet" title=" ultraviolet"> ultraviolet</a> </p> <a href="https://publications.waset.org/abstracts/168345/cutaneous-sarcoidosis-treated-with-narrow-band-ultraviolet-b-nbuvb-phototherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/168345.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">73</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">10</span> The Gold Standard Treatment Plan for Vitiligo: A Review on Conventional and Updated Treatment Methods</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kritin%20K.%20Verma">Kritin K. Verma</a>, <a href="https://publications.waset.org/abstracts/search?q=Brian%20L.%20Ransdell"> Brian L. Ransdell</a> </p> <p class="card-text"><strong>Abstract:</strong></p> White patches are a symptom of vitiligo, a chronic autoimmune dermatological condition that causes a loss of pigmentation in the skin. Vitiligo can cause issues of self-esteem and quality of life while also progressing the development of other autoimmune diseases. Current treatments in allopathy and homeopathy exist; some treatments have been found to be toxic, whereas others have been helpful. Allopathy has seemed to offer several treatment plans, such as phototherapy, skin lightening preparations, immunosuppressive drugs, combined modality therapy, and steroid medications to improve vitiligo. This presentation will review the FDA-approved topical cream, Opzelura, a JAK inhibitor, and its effects on limiting vitiligo progression. Meanwhile, other non-conventional methods, such as Arsenic Sulphuratum Flavum used in homeopathy, will be debunked based on current literature. Most treatments still serve to arrest progression and induce skin repigmentation. Treatment plans may differ between patients due to depigmentation location on the skin. Since there is no gold standard plan for treating patients with vitiligo, the oral presentation will review all topical and systemic pharmacological therapies that fight the depigmentation of the skin and categorize their validity from a systematic review of the literature. Since treatment plans are limited in nature, all treatment methods will be mentioned and an attempt will be made to make a golden standard treatment process for these patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=vitiligo" title="vitiligo">vitiligo</a>, <a href="https://publications.waset.org/abstracts/search?q=phototherapy" title=" phototherapy"> phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=immunosuppressive%20drugs" title=" immunosuppressive drugs"> immunosuppressive drugs</a>, <a href="https://publications.waset.org/abstracts/search?q=skin%20lightening%20preparations" title=" skin lightening preparations"> skin lightening preparations</a>, <a href="https://publications.waset.org/abstracts/search?q=combined%20modality%20therapy" title=" combined modality therapy"> combined modality therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=arsenic%20sulphuratum%20flavum" title=" arsenic sulphuratum flavum"> arsenic sulphuratum flavum</a>, <a href="https://publications.waset.org/abstracts/search?q=homeopathy" title=" homeopathy"> homeopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=allopathy" title=" allopathy"> allopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=golden%20standard" title=" golden standard"> golden standard</a>, <a href="https://publications.waset.org/abstracts/search?q=Opzelura" title=" Opzelura"> Opzelura</a> </p> <a href="https://publications.waset.org/abstracts/156036/the-gold-standard-treatment-plan-for-vitiligo-a-review-on-conventional-and-updated-treatment-methods" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/156036.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">87</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">9</span> Clinical Audit on the Introduction of Apremilast into Ireland</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=F.%20O%E2%80%99Dowd">F. O’Dowd</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20Murphy"> G. Murphy</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Roche"> M. Roche</a>, <a href="https://publications.waset.org/abstracts/search?q=E.%20Shudell"> E. Shudell</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Keane"> F. Keane</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20O%E2%80%99Kane"> M. O’Kane</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Intoduction: Apremilast (Otezla®) is an oral phosphodiesterase-4 (PDE4) inhibitor indicated for treatment of adult patients with moderate to severe plaque psoriasis who have contraindications to have failed or intolerant of standard systemic therapy and/or phototherapy; and adult patients with active psoriatic arthritis. Apremilast influences intracellular regulation of inflammatory mediators. Two randomized, placebo-controlled trials evaluating apremilast in 1426 patients with moderate to severe plague psoriasis (ESTEEM 1 and 2) demonstrated that the commonest adverse reactions (AE’s) leading to discontinuation were nausea (1.6%), diarrhoea (1.0%), and headaches (0.8%). The overall proportion of subjects discontinuing due to adverse reactions was 6.1%. At week 16 these trials demonstrated significant more apremilast-treated patients (33.1%) achieved the primary end point PASI-75 than placebo (5.3%). We began prescribing apremilast in July 2015. Aim: To evaluate efficacy and tolerability of apremilast in an Irish teaching hospital psoriasis population. Methods: A proforma documenting clinical evaluation parameters, prior treatment experience and AE’s; was completed prospectively on all patients commenced on apremilast since July 2015 – July 2017. Data was collected at week 0,6,12,24,36 and week 52 with 20/71 patients having passed week 52. Efficacy was assessed using Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI). AE’s documented included GI effects, infections, changes in weight and mood. Retrospective chart review and telephone review was utilised for missing data. Results: A total of 71 adult subjects (38 male, 33 female; age range 23-57), with moderate to severe psoriasis, were evaluated. Prior treatment: 37/71 (52%) were systemic/biologic/phototherapy naïve; 14/71 (20%) has prior phototherapy alone;20/71 (28%) had previous systemic/biologic exposure; 12/71 (17%) had both psoriasis and psoriatic arthritis. PASI responses: mean baseline PASI was 10.1 and DLQI was 15.Week 6: N=71, n=15 (21%) achieved PASI 75. Week 12: N= 48, n=6 (13%) achieved a PASI 100%; n=16 (34.5%) achieved a PASI 75. Week 24: N=40, n=10 (25%) achieved a PASI 100; n=15 (37.5%) achieved a PASI 75. Week 52: N= 20, n=4 (20%) achieved a PASI 100; n= 16 (80%) achieved a PASI 75. (N= number of pts having passed the time point indicated, n= number of pts (out of N) achieving PASI or DLQI responses at that time). DLQI responses: week 24: N= 40, n=30 (75%) achieved a DLQI score of 0; n=5 (12.5%) achieved a DLQI score of 1; n=1 (2.5%) achieved a DLQI score of 10 (due to lack of efficacy). Adverse Events: The proportion of patients that discontinued treatment due to AE’s was n=7 (9.8%). One patient experienced nausea alleviated by dose reduction; another developed significant dysgeusia for certain foods, both continued therapy. Two patients lost 2-3 kg. Conclusion: Initial Irish patient experience of Apremilast appears comparable to that observed in trials with good efficacy and tolerability. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Apremilast" title="Apremilast">Apremilast</a>, <a href="https://publications.waset.org/abstracts/search?q=introduction" title=" introduction"> introduction</a>, <a href="https://publications.waset.org/abstracts/search?q=Ireland" title=" Ireland"> Ireland</a>, <a href="https://publications.waset.org/abstracts/search?q=clinical%20audit" title=" clinical audit"> clinical audit</a> </p> <a href="https://publications.waset.org/abstracts/74418/clinical-audit-on-the-introduction-of-apremilast-into-ireland" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/74418.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">149</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">8</span> Psoriasis Diagnostic Test Development: Exploratory Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Salam%20N.%20Abdo">Salam N. Abdo</a>, <a href="https://publications.waset.org/abstracts/search?q=Orien%20L.%20Tulp"> Orien L. Tulp</a>, <a href="https://publications.waset.org/abstracts/search?q=George%20P.%20Einstein"> George P. Einstein</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The purpose of this exploratory study was to gather the insights into psoriasis etiology, treatment, and patient experience, for developing psoriasis and psoriatic arthritis diagnostic test. Data collection methods consisted of a comprehensive meta-analysis of relevant studies and psoriasis patient survey. Established meta-analysis guidelines were used for the selection and qualitative comparative analysis of psoriasis and psoriatic arthritis research studies. Only studies that clearly discussed psoriasis etiology, treatment, and patient experience were reviewed and analyzed, to establish a qualitative data base for the study. Using the insights gained from meta-analysis, an existing psoriasis patient survey was modified and administered to collect additional data as well as triangulate the results. The hypothesis is that specific types of psoriatic disease have specific etiology and pathophysiologic pattern. The following etiology categories were identified: bacterial, environmental/microbial, genetic, immune, infectious, trauma/stress, and viral. Additional results, obtained from meta-analysis and confirmed by patient survey, were the common age of onset (early to mid-20s) and type of psoriasis (plaque; mild; symmetrical; scalp, chest, and extremities, specifically elbows and knees). Almost 70% of patients reported no prescription drug use due to severe side effects and prohibitive cost. These results will guide the development of psoriasis and psoriatic arthritis diagnostic test. The significant number of medical publications classified psoriatic arthritis disease as inflammatory of an unknown etiology. Thus numerous meta-analyses struggle to report any meaningful conclusions since no definitive results have been reported to date. Therefore, return to the basics is an essential step to any future meaningful results. To date, medical literature supports the fact that psoriatic disease in its current classification could be misidentifying subcategories, which in turn hinders the success of studies conducted to date. Moreover, there has been an enormous commercial support to pursue various immune-modulation therapies, thus following a narrow hypothesis/mechanism of action that is yet to yield resolution of disease state. Recurrence and complications may be considered unacceptable in a significant number of these studies. The aim of the ongoing study is to focus on a narrow subgroup of patient population, as identified by this exploratory study via meta-analysis and patient survey, and conduct an exhaustive work up, aiming at mechanism of action and causality before proposing a cure or therapeutic modality. Remission in psoriasis has been achieved and documented in medical literature, such as immune-modulation, phototherapy, various over-the-counter agents, including salts and tar. However, there is no psoriasis and psoriatic arthritis diagnostic test to date, to guide the diagnosis and treatment of this debilitating and, thus far, incurable disease. Because psoriasis affects approximately 2% of population, the results of this study may affect the treatment and improve the quality of life of a significant number of psoriasis patients, potentially millions of patients in the United States alone and many more millions worldwide. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=biologics" title="biologics">biologics</a>, <a href="https://publications.waset.org/abstracts/search?q=early%20diagnosis" title=" early diagnosis"> early diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=etiology" title=" etiology"> etiology</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20disease" title=" immune disease"> immune disease</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20modulation%20therapy" title=" immune modulation therapy"> immune modulation therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=inflammation%20skin%20disorder" title=" inflammation skin disorder"> inflammation skin disorder</a>, <a href="https://publications.waset.org/abstracts/search?q=phototherapy" title=" phototherapy"> phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=plaque%20psoriasis" title=" plaque psoriasis"> plaque psoriasis</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis" title=" psoriasis"> psoriasis</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20classification" title=" psoriasis classification"> psoriasis classification</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20disease%20marker" title=" psoriasis disease marker"> psoriasis disease marker</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20diagnostic%20test" title=" psoriasis diagnostic test"> psoriasis diagnostic test</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20marker" title=" psoriasis marker"> psoriasis marker</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20mechanism%20of%20action" title=" psoriasis mechanism of action"> psoriasis mechanism of action</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriasis%20treatment" title=" psoriasis treatment"> psoriasis treatment</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriatic%20arthritis" title=" psoriatic arthritis"> psoriatic arthritis</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriatic%20disease" title=" psoriatic disease"> psoriatic disease</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriatic%20disease%20marker" title=" psoriatic disease marker"> psoriatic disease marker</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriatic%20patient%20experience" title=" psoriatic patient experience"> psoriatic patient experience</a>, <a href="https://publications.waset.org/abstracts/search?q=psoriatic%20patient%20quality%20of%20life" title=" psoriatic patient quality of life"> psoriatic patient quality of life</a>, <a href="https://publications.waset.org/abstracts/search?q=remission" title=" remission"> remission</a>, <a href="https://publications.waset.org/abstracts/search?q=salt%20therapy" title=" salt therapy"> salt therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=targeted%20immune%20therapy" title=" targeted immune therapy"> targeted immune therapy</a> </p> <a href="https://publications.waset.org/abstracts/105073/psoriasis-diagnostic-test-development-exploratory-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/105073.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">118</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">7</span> Ab-initio Calculations on the Mechanism of Action of Platinum and Ruthenium Complexes in Phototherapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Eslam%20Dabbish">Eslam Dabbish</a>, <a href="https://publications.waset.org/abstracts/search?q=Fortuna%20Ponte"> Fortuna Ponte</a>, <a href="https://publications.waset.org/abstracts/search?q=Stefano%20Scoditti"> Stefano Scoditti</a>, <a href="https://publications.waset.org/abstracts/search?q=Emilia%20Sicilia"> Emilia Sicilia</a>, <a href="https://publications.waset.org/abstracts/search?q=Gloria%20Mazzone"> Gloria Mazzone</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The medical techniques based on the use of light for activating the drug are occupying a prominent place in the cancer treatment due to their selectivity that contributes to reduce undesirable side effects of conventional chemotherapy. Among these therapeutic treatments, photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) are emerging as complementary approaches for selective destruction of neoplastic tissue through direct cellular damage. Both techniques rely on the employment of a molecule, photosensitizer (PS), able to absorb within the so-called therapeutic window. Thus, the exposure to light of otherwise inert molecules promotes the population of excited states of the drug, that in PDT are able to produce the cytotoxic species, such as 1O2 and other ROS, in PACT can be responsible of the active species release or formation. Following the success of cisplatin in conventional treatments, many other transition metal complexes were explored as anticancer agents for applications in different medical approaches, including PDT and PACT, in order to improve their chemical, biological and photophysical properties. In this field, several crucial characteristics of candidate PSs can be accurately predicted from first principle calculations, especially in the framework of density functional theory and its time-dependent formulation, contributing to the understanding of the entire photochemical pathways involved which can ultimately help in improving the efficiency of a drug. A brief overview of the outcomes on some platinum and ruthenium-based PSs proposed for the application in the two phototherapies will be provided. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=TDDFT" title="TDDFT">TDDFT</a>, <a href="https://publications.waset.org/abstracts/search?q=metal%20complexes" title=" metal complexes"> metal complexes</a>, <a href="https://publications.waset.org/abstracts/search?q=PACT" title=" PACT"> PACT</a>, <a href="https://publications.waset.org/abstracts/search?q=PDT" title=" PDT"> PDT</a> </p> <a href="https://publications.waset.org/abstracts/152251/ab-initio-calculations-on-the-mechanism-of-action-of-platinum-and-ruthenium-complexes-in-phototherapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/152251.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">103</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">6</span> Evaluation of Immune Checkpoint Inhibitors in Cancer Therapy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mir%20Mohammad%20Reza%20Hosseini">Mir Mohammad Reza Hosseini</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In new years immune checkpoint inhibitors have gathered care as being one of the greatest talented kinds of immunotherapy on the prospect. There has been a specific emphasis on the immune checkpoint molecules, cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1). In 2011, ipilimumab, the primary antibody obstructive an immune checkpoint (CTLA4) was authorized. It is now documented that recognized tumors have many devices of overpowering the antitumor immune response, counting manufacture of repressive cytokines, staffing of immunosuppressive immune cells, and upregulation of coinhibitory receptors recognized as immune checkpoints. This was fast followed by the growth of monoclonal antibodies directing PD1 (pembrolizumab and nivolumab) and PDL1 (atezolizumab and durvalumab). Anti-PD1/PDL1 antibodies have developed some of the greatest extensively set anticancer therapies. We also compare and difference their present place in cancer therapy and designs of immune-related toxicities and deliberate the role of dual immune checkpoint inhibition and plans for the organization of immune-related opposing proceedings. In this review, the employed code and present growth of numerous immune checkpoint inhibitors are abridged, while the communicating device and new development of Immune checkpoint inhibitors in cancer therapy-based synergistic therapies with additional immunotherapy, chemotherapy, phototherapy, and radiotherapy in important and clinical educations in the historical 5 years are portrayed and tinted. Lastly, we disapprovingly measure these methods and effort to find their fortes and faintness based on pre-clinical and clinical information. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=checkpoint" title="checkpoint">checkpoint</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20therapy" title=" cancer therapy"> cancer therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=PD-1" title=" PD-1"> PD-1</a>, <a href="https://publications.waset.org/abstracts/search?q=PDL-1" title=" PDL-1"> PDL-1</a>, <a href="https://publications.waset.org/abstracts/search?q=CTLA4" title=" CTLA4"> CTLA4</a>, <a href="https://publications.waset.org/abstracts/search?q=immunosuppressive" title=" immunosuppressive"> immunosuppressive</a> </p> <a href="https://publications.waset.org/abstracts/143738/evaluation-of-immune-checkpoint-inhibitors-in-cancer-therapy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/143738.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">168</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">5</span> Upconversion Nanomaterials for Applications in Life Sciences and Medicine</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yong%20Zhang">Yong Zhang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Light has proven to be useful in a wide range of biomedical applications such as fluorescence imaging, photoacoustic imaging, optogenetics, photodynamic therapy, photothermal therapy, and light controlled drug/gene delivery. Taking photodynamic therapy (PDT) as an example, PDT has been proven clinically effective in early lung cancer, bladder cancer, head, and neck cancer and is the primary treatment for skin cancer as well. However, clinical use of PDT is severely constrained by the low penetration depth of visible light through thick tissue, limiting its use to target regions only a few millimeters deep. One way to enhance the range is to use invisible near-infrared (NIR) light within the optical window (700–1100nm) for biological tissues, extending the depth up to 1cm with no observable damage to the intervening tissue. We have demonstrated use of NIR-to-visible upconversion fluorescent nanoparticles (UCNPs), emitting visible fluorescence when excited by a NIR light at 980nm, as a nanotransducer for PDT to convert deep tissue-penetrating NIR light to visible light suitable for activating photosensitizers. The unique optical properties of UCNPs enable the upconversion wavelength to be tuned and matched to the activation absorption wavelength of the photosensitizer. At depths beyond 1cm, however, tissue remains inaccessible to light even within the NIR window, and this critical depth limitation renders existing phototherapy ineffective against most deep-seated cancers. We have demonstrated some new treatment modalities for deep-seated cancers based on UCNP hydrogel implants and miniaturized, wirelessly powered optoelectronic devices for light delivery to deep tissues. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=upconversion" title="upconversion">upconversion</a>, <a href="https://publications.waset.org/abstracts/search?q=fluorescent" title=" fluorescent"> fluorescent</a>, <a href="https://publications.waset.org/abstracts/search?q=nanoparticle" title=" nanoparticle"> nanoparticle</a>, <a href="https://publications.waset.org/abstracts/search?q=bioimaging" title=" bioimaging"> bioimaging</a>, <a href="https://publications.waset.org/abstracts/search?q=photodynamic%20therapy" title=" photodynamic therapy"> photodynamic therapy</a> </p> <a href="https://publications.waset.org/abstracts/145172/upconversion-nanomaterials-for-applications-in-life-sciences-and-medicine" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/145172.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">161</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">4</span> A Non-Invasive Neonatal Jaundice Screening Device Measuring Bilirubin on Eyes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Li%20Shihao">Li Shihao</a>, <a href="https://publications.waset.org/abstracts/search?q=Dieter%20Trau"> Dieter Trau</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bilirubin is a yellow substance that is made when the body breaks down old red blood cells. High levels of bilirubin can cause jaundice, a condition that makes the newborn's skin and the white part of the eyes look yellow. Jaundice is a serial-killer in developing countries in Southeast Asia such as Myanmar and most parts of Africa where jaundice screening is largely unavailable. Worldwide, 60% of newborns experience infant jaundice. One in ten will require therapy to prevent serious complications and lifelong neurologic sequelae. Limitations of current solutions: - Blood test: Blood tests are painful may largely unavailable in poor areas of developing countries, and also can be costly and unsafe due to the insufficient investment and lack of access to health care systems. - Transcutaneous jaundice-meter: 1) can only provide reliable results to caucasian newborns, due to skin pigmentations since current technologies measure bilirubin by the color of the skin. Basically, the darker the skin is, the harder to measure, 2) current jaundice meters are not affordable for most underdeveloped areas in Africa like Kenya and Togo, 3) fat tissue under the skin also influences the accuracy, which will give overestimated results, 4) current jaundice meters are not reliable after treatment (phototherapy) because bilirubin levels underneath the skin will be reduced first, while overall levels may be quite high. Thus, there is an urgent need for a low-cost non-invasive device, which can be effective not only for caucasian babies but also Asian and African newborns, to save lives at the most vulnerable time and prevent any complications like brain damage. Instead of measuring bilirubin on skin, we proposed a new method to do the measurement on the sclera, which can avoid the difference of skin pigmentations and ethnicities, due to the necessity for the sclera to be white regardless of racial background. This is a novel approach for measuring bilirubin by an optical method of light reflection off the white part of the eye. Moreover, the device is connected to a smart device, which can provide a user-friendly interface and the ability to record the clinical data continuously A disposable eye cap will be provided avoiding contamination and fixing the distance to the eye. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jaundice" title="Jaundice">Jaundice</a>, <a href="https://publications.waset.org/abstracts/search?q=bilirubin" title=" bilirubin"> bilirubin</a>, <a href="https://publications.waset.org/abstracts/search?q=non-invasive" title=" non-invasive"> non-invasive</a>, <a href="https://publications.waset.org/abstracts/search?q=sclera" title=" sclera"> sclera</a> </p> <a href="https://publications.waset.org/abstracts/50345/a-non-invasive-neonatal-jaundice-screening-device-measuring-bilirubin-on-eyes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/50345.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">236</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">3</span> Rare DCDC2 Mutation Causing Renal-Hepatic Ciliopathy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Atitallah%20Sofien">Atitallah Sofien</a>, <a href="https://publications.waset.org/abstracts/search?q=Bouyahia%20Olfa"> Bouyahia Olfa</a>, <a href="https://publications.waset.org/abstracts/search?q=Attar%20Souleima"> Attar Souleima</a>, <a href="https://publications.waset.org/abstracts/search?q=Missaoui%20Nada"> Missaoui Nada</a>, <a href="https://publications.waset.org/abstracts/search?q=Ben%20Rabeh%20Rania"> Ben Rabeh Rania</a>, <a href="https://publications.waset.org/abstracts/search?q=Yahyaoui%20Salem"> Yahyaoui Salem</a>, <a href="https://publications.waset.org/abstracts/search?q=Mazigh%20Sonia"> Mazigh Sonia</a>, <a href="https://publications.waset.org/abstracts/search?q=Boukthir%20Samir"> Boukthir Samir</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Ciliopathies are a spectrum of diseases that have in common a defect in the synthesis of ciliary proteins. It is a rare cause of neonatal cholestasis. Clinical presentation varies extremely, and the main affected organs are the kidneys, liver, and pancreas. Methodology: This is a descriptive case report of a newborn who was admitted for exploration of neonatal cholestasis in the Paediatric Department C at the Children’s Hospital of Tunis, where the investigations concluded with a rare genetic mutation. Results: This is the case of a newborn male with no family history of hepatic and renal diseases, born to consanguineous parents, and from a well-monitored uneventful pregnancy. He developed jaundice on the second day of life, for which he received conventional phototherapy in the neonatal intensive care unit. He was admitted at 15 days for mild bronchiolitis. On clinical examination, intense jaundice was noted with normal stool and urine colour. Initial blood work showed an elevation in conjugated bilirubin and a high gamma-glutamyl transferase level. Transaminases and prothrombin time were normal. Abdominal sonography revealed hepatomegaly, splenomegaly, and undifferentiated renal cortex with bilateral medullar micro-cysts. Kidney function tests were normal. The infant received ursodeoxycholic acid and vitamin therapy. Genetic testing showed a homozygous mutation in the DCDC2 gene that hadn’t been documented before confirming the diagnosis of renal-hepatic ciliopathy. The patient has regular follow-ups, and his conjugated bilirubin and gamma-glutamyl transferase levels have been decreasing. Conclusion: Genetic testing has revolutionized the approach to etiological diagnosis in pediatric cholestasis. It enables personalised treatment strategies to better enhance the quality of life of patients and prevent potential complications following adequate long-term monitoring. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cholestasis" title="cholestasis">cholestasis</a>, <a href="https://publications.waset.org/abstracts/search?q=newborn" title=" newborn"> newborn</a>, <a href="https://publications.waset.org/abstracts/search?q=ciliopathy" title=" ciliopathy"> ciliopathy</a>, <a href="https://publications.waset.org/abstracts/search?q=DCDC2" title=" DCDC2"> DCDC2</a>, <a href="https://publications.waset.org/abstracts/search?q=genetic" title=" genetic"> genetic</a> </p> <a href="https://publications.waset.org/abstracts/175773/rare-dcdc2-mutation-causing-renal-hepatic-ciliopathy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/175773.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">63</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2</span> Pioneering Technology of Night Photo-Stimulation of the Brain Lymphatic System: Therapy of Brain Diseases during Sleep</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Semyachkina-Glushkovskaya%20Oxana">Semyachkina-Glushkovskaya Oxana</a>, <a href="https://publications.waset.org/abstracts/search?q=Fedosov%20Ivan"> Fedosov Ivan</a>, <a href="https://publications.waset.org/abstracts/search?q=Blokhina%20Inna"> Blokhina Inna</a>, <a href="https://publications.waset.org/abstracts/search?q=Terskov%20Andrey"> Terskov Andrey</a>, <a href="https://publications.waset.org/abstracts/search?q=Evsukova%20Arina"> Evsukova Arina</a>, <a href="https://publications.waset.org/abstracts/search?q=Elovenko%20Daria"> Elovenko Daria</a>, <a href="https://publications.waset.org/abstracts/search?q=Adushkina%20Viktoria"> Adushkina Viktoria</a>, <a href="https://publications.waset.org/abstracts/search?q=Dubrovsky%20Alexander"> Dubrovsky Alexander</a>, <a href="https://publications.waset.org/abstracts/search?q=J%C3%BCrgen%20Kurths"> Jürgen Kurths</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In modern neurobiology, sleep is considered a novel biomarker and a promising therapeutic target for brain diseases. This is due to recent discoveries of the nighttime activation of the brain lymphatic system (BLS), playing an important role in the removal of wastes and toxins from the brain and contributes neuroprotection of the central nervous system (CNS). In our review, we discuss that night stimulation of BLS might be a breakthrough strategy in a new treatment of Alzheimer’s and Parkinson’s disease, stroke, brain trauma, and oncology. Although this research is in its infancy, however, there are pioneering and promising results suggesting that night transcranial photostimulation (tPBM) stimulates more effectively lymphatic removal of amyloid-beta from mouse brain than daily tPBM that is associated with a greater improvement of the neurological status and recognition memory of animals. In our previous study, we discovered that tPBM modulates the tone and permeability of the lymphatic endothelium by stimulating NO formation, promoting lymphatic clearance of wastes and toxins from the brain tissues. We also demonstrate that tPBM can also lead to angio- and lymphangiogenesis, which is another mechanism underlying tPBM-mediated stimulation of BLS. Thus, photo-augmentation of BLS might be a promising therapeutic target for preventing or delaying brain diseases associated with BLS dysfunction. Here we present pioneering technology for simultaneous tPBM in humans and sleep monitoring for stimulation of BLS to remove toxins from CNS and modulation of brain immunity. The wireless-controlled gadget includes a flexible organic light-emitting diode (LED) source that is controlled directly by a sleep-tracking device via a mobile application. The designed autonomous LED source is capable of providing the required therapeutic dose of light radiation at a certain region of the patient’s head without disturbing of sleeping patient. To minimize patients' discomfort, advanced materials like flexible organic LEDs were used. Acknowledgment: This study was supported by RSF project No. 23-75-30001. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=brain%20diseases" title="brain diseases">brain diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=brain%20lymphatic%20system" title=" brain lymphatic system"> brain lymphatic system</a>, <a href="https://publications.waset.org/abstracts/search?q=phototherapy" title=" phototherapy"> phototherapy</a>, <a href="https://publications.waset.org/abstracts/search?q=sleep" title=" sleep"> sleep</a> </p> <a href="https://publications.waset.org/abstracts/166239/pioneering-technology-of-night-photo-stimulation-of-the-brain-lymphatic-system-therapy-of-brain-diseases-during-sleep" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/166239.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">72</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1</span> Strengthening Facility-Based Systems to Improve Access to In-Patient Care for Sick Newborns in Brong Ahafo Region, Ghana</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Paulina%20Clara%20Appiah">Paulina Clara Appiah</a>, <a href="https://publications.waset.org/abstracts/search?q=Kofi%20Issah"> Kofi Issah</a>, <a href="https://publications.waset.org/abstracts/search?q=Timothy%20Letsa"> Timothy Letsa</a>, <a href="https://publications.waset.org/abstracts/search?q=Kennedy%20Nartey"> Kennedy Nartey</a>, <a href="https://publications.waset.org/abstracts/search?q=Amanua%20Chinbuah"> Amanua Chinbuah</a>, <a href="https://publications.waset.org/abstracts/search?q=Adoma%20Dwomo-Fokuo"> Adoma Dwomo-Fokuo</a>, <a href="https://publications.waset.org/abstracts/search?q=Jacqeline%20G.%20Asibey"> Jacqeline G. Asibey</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The Every Newborn Action Plan provides evidence–based interventions to end preventable deaths in high burden countries. Brong Ahafo Region is one of ten regions in Ghana with less than half of its district hospitals having sick newborn units. Facility-based neonatal care is not prioritized and under-funded, and there is also inadequate knowledge and competence to manage the sick. The aim of this intervention was to make available in–patient care for sick newborns in all 19 district hospitals through the strengthening of facility-based systems. Methods: With the development and dissemination of the National Newborn Strategy and Action Plan 2014-2018, the country was able to attract PATH which provided the region with basic resuscitation equipment, supported hospital providers’ capacity building in Helping Babies Breathe, Essential Care of Every Baby, Infection Prevention and Management and held a symposia on managing the sick newborn. Newborn advocacy was promoted through newborn champions at the facility and community levels. Hospital management was then able to mobilize resources from communities, corporate organizations and from internally generated funds; created or expanded sick newborn care units and provided essential medicines and equipment. Kangaroo Mother Care was initiated in 6 hospitals. Pediatric specialist outreach services initiated comprised telephone consultations, teaching ward rounds and participating in perinatal death audits meetings. Newborn data capture and management was improved through the provision and training on the use of standard registers provided from the national level. Results: From February 2015 to November 2017, hospitals with sick newborn units increased from 7 to 19 (37%-100%). 180 pieces each of newborn ventilation bags and masks size 0, 1 and penguin suction bulbs were distributed to the hospitals, in addition to 20 newborn mannequin sets and 90 small clinical reminder posters. 802 providers (96.9%) were trained in resuscitation, of which 96% were successfully followed up in 6 weeks, 91% in 6 months and 80% in 12 months post-training. 53 clinicians (65%) were trained and mentored to manage sick newborns. 56 specialist teaching ward rounds were conducted. Data completeness improved from 92.6% - 99.9%. Availability of essential medicines improved from 11% to 100%. Number of hospital cots increased from 116 to 248 (214%). Cot occupancy rate increased from 57.4% to 92.5%. Hospitals with phototherapy equipment increased from 0 to 12 (63%). Hospitals with incubators increased from 1 to 12 (5%-63%). Newborn deaths among admissions reduced from 6.3% to 5.4%. Conclusion: Access to in-patient care increased significantly. Newborn advocacy successfully mobilized resources required for strengthening facility –based systems. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=facility-based%20systems" title="facility-based systems">facility-based systems</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghana" title=" Ghana"> Ghana</a>, <a href="https://publications.waset.org/abstracts/search?q=in-patient%20care" title=" in-patient care"> in-patient care</a>, <a href="https://publications.waset.org/abstracts/search?q=newborn%20advocacy" title=" newborn advocacy"> newborn advocacy</a> </p> <a href="https://publications.waset.org/abstracts/93972/strengthening-facility-based-systems-to-improve-access-to-in-patient-care-for-sick-newborns-in-brong-ahafo-region-ghana" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/93972.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">249</span> </span> </div> </div> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>